Cambridge, Massachusetts-based biotech firm Orbital Therapeutics closed its ARCH Venture Partners-led Series A round at $270M.
Incoming funds will enable the firm to expand the scope of its
RNA-based medicines, advance research, accelerate programs, and scale
the firm. The firm is currently working on next-generation vaccines,
immunomodulation, and protein replacement.
- Orbital launched seven months ago with an undisclosed investment from ARCH and Andreessen Horowitz.
- A16z's Bio + Health division participated in the current round along with another previous backer Newpath Ventures.
- New
investors joining the funding round include Abu Dhabi Growth Fund,
Invus, Casdin Capital, Moore Strategic Ventures, and others.
- The firm strengthened its C-suite team with two new hires: Niru Subramanian as chief operating officer and Jonathan Piazza as chief financial officer.
- Since the last fundraising, the firm acquired an undisclosed startup and inked a strategic partnership with Beam Therapeutics.
